115 related articles for article (PubMed ID: 10460868)
1. Permanently reduced plasma ionized magnesium among renal transplant recipients on cyclosporine.
Vannini SD; Mazzola BL; Rodoni L; Truttmann AC; Wermuth B; Bianchetti MG; Ferrari P
Transpl Int; 1999; 12(4):244-9. PubMed ID: 10460868
[TBL] [Abstract][Full Text] [Related]
2. Plasma (total and ionized), erythrocyte and platelet magnesium levels in renal transplant recipients during cyclosporine and/or azathioprine treatment.
Allegra A; Corica F; Ientile R; Corsonello A; Sparacino V; Accettola F; Caputo F; Macaione S; Buemi M
Magnes Res; 1998 Mar; 11(1):11-8. PubMed ID: 9595545
[TBL] [Abstract][Full Text] [Related]
3. Ionized and total magnesium levels in cyclosporin-treated renal transplant recipients: relationship with cholesterol and cyclosporin levels.
Markell MS; Altura BT; Barbour RL; Altura BM
Clin Sci (Lond); 1993 Sep; 85(3):315-8. PubMed ID: 8403804
[TBL] [Abstract][Full Text] [Related]
4. Mycophenolate mofetil immunosuppression in high-risk renal transplant recipients.
Abouna GM; al Arrayed AS; Farid E; Awad CK; Sharqawi SA; Tantawi M
Transplant Proc; 1998 Dec; 30(8):4077-8. PubMed ID: 9865302
[No Abstract] [Full Text] [Related]
5. Single-center study utilizing C(2) level as monitoring tool in de novo renal transplant recipients treated with Neoral.
Keshavamurthy M; Al Ahmadi I; Mohammed Raza S; Baynton R; Al Meshari K; Al Shaibani K
Transplant Proc; 2001; 33(7-8):3112-4. PubMed ID: 11750338
[No Abstract] [Full Text] [Related]
6. Triple therapy with mycophenolate mofetil versus azathioprine.
Muñiz ML; Amenabar J; Gómez-Ullate P; Urbizu J; Lampreabe I
Transplant Proc; 1999; 31(1-2):1144-6. PubMed ID: 10083512
[No Abstract] [Full Text] [Related]
7. A pilot study of cyclosporine withdrawal in stable renal transplant recipients after azathioprine-mycophenolate mofetil conversion.
Thervet E; Morelon E; Ducloux D; Bererhi L; Noël LH; Janin A; Bedrossian J; Puget S; Chalopin JM; Mihatsch M; Legendre C; Kreis H
Transplant Proc; 2000 Dec; 32(8):2778. PubMed ID: 11134800
[No Abstract] [Full Text] [Related]
8. Clinical study of FK 506 in renal transplant recipients.
Youhua Z; Zhinlian M; Liming W
Transplant Proc; 2000 Nov; 32(7):1704. PubMed ID: 11119900
[No Abstract] [Full Text] [Related]
9. Long-term calcineurin inhibition and magnesium balance after renal transplantation.
Mazzola BL; Vannini SD; Truttmann AC; von Vigier RO; Wermuth B; Ferrari P; Bianchetti MG
Transpl Int; 2003 Feb; 16(2):76-81. PubMed ID: 12595968
[TBL] [Abstract][Full Text] [Related]
10. Gastric emptying time in renal transplant recipients treated with cyclosporine.
Ozkaya O; Derici U; Buyan N; Dalgic A; Dalgic B; Cingi E; Kitapci M; Sindel S; Hasanoglu E
Transplant Proc; 2003 Dec; 35(8):2927-30. PubMed ID: 14697940
[TBL] [Abstract][Full Text] [Related]
11. Successful withdrawal of steroids in pediatric renal transplant recipients receiving cyclosporine A and mycophenolate mofetil treatment: results after four years.
Höcker B; John U; Plank C; Wühl E; Weber LT; Misselwitz J; Rascher W; Mehls O; Tönshoff B
Transplantation; 2004 Jul; 78(2):228-34. PubMed ID: 15280683
[TBL] [Abstract][Full Text] [Related]
12. Triple therapy with mycophenolate mofetil, cyclosporine, and prednisone in renal transplantation.
Crespo JF; Górriz JL; Sancho A; Avila A; Alcoy E; Pallardó LM
Transplant Proc; 1999 Sep; 31(6):2261-2. PubMed ID: 10500568
[No Abstract] [Full Text] [Related]
13. Correlation between serum magnesium and blood cyclosporine A concentrations in renal transplant recipients.
Thakur V; Kumar R; Dhawan IK
Ann Clin Biochem; 2002 Jan; 39(Pt 1):70-2. PubMed ID: 11853195
[TBL] [Abstract][Full Text] [Related]
14. Hypomagnesemia and renal magnesium wasting in renal transplant recipients receiving cyclosporine.
Barton CH; Vaziri ND; Martin DC; Choi S; Alikhani S
Am J Med; 1987 Oct; 83(4):693-9. PubMed ID: 3314493
[TBL] [Abstract][Full Text] [Related]
15. Lipid profile during azathioprine or mycophenolate mofetil combinations with cyclosporine and steroids.
Akman B; Uyar M; Afsar B; Sezer S; Ozdemir FN; Haberal M
Transplant Proc; 2007; 39(1):135-7. PubMed ID: 17275490
[TBL] [Abstract][Full Text] [Related]
16. Selective CellCept therapy in high-risk renal transplant recipients.
Isenberg A; Singh TP; Shen GK; Freed BM; Conti DJ
Transplant Proc; 1998 Jun; 30(4):1188-9. PubMed ID: 9636480
[No Abstract] [Full Text] [Related]
17. Mycophenolate mofetil and reduction in cyclosporine dosage for chronic renal allograft dysfunction.
Islam MS; Francos GC; Dunn SR; Burke JF
Transplant Proc; 1998 Aug; 30(5):2230-1. PubMed ID: 9723452
[No Abstract] [Full Text] [Related]
18. Effect of glucocorticoid-free immunosuppressive protocol on serum lipids in renal transplant patients.
Nowacka-Cieciura E; Soluch L; Cieciura T; Lewandowska D; Durlik M; Shaibani B; Serafinowicz A; Szmidt J; Rowiński W; Lao M
Transplant Proc; 2000 Sep; 32(6):1339-43. PubMed ID: 10995973
[No Abstract] [Full Text] [Related]
19. Mycophenolate mofetil with lower cyclosporine dose in high-risk renal transplant recipients.
Esmeraldo RM; Donadi MO; Oliveira ML; Ponte CN; Pinheiro PM
Transplant Proc; 1999 Nov; 31(7):3007-8. PubMed ID: 10578367
[No Abstract] [Full Text] [Related]
20. Impact of cyclosporine A on magnesium homeostasis: clinical observation in lung transplant recipients and experimental study in mice.
Sabbagh F; El Tawil Z; Lecerf F; Hulin A; Maurois P; Dartevelle P; Bac P; German-Fattal M
Transplantation; 2008 Aug; 86(3):436-44. PubMed ID: 18698248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
